Multiple sclerosis (MS) is an immune-mediated neurodegenerative disorder of the human
central nervous system (CNS) that typically affects young adults. This enigmatic and
destructive disorder of both white matter and gray matter of CNS affects individuals
with predisposing genetic background and probably requires a provoking environmental
factor, such as exposure to a viral agent, to initiate the disease process [[1], [2], [3]]. In the United States, MS is the leading cause of neurological disability in young
individuals. Clinically, MS most often follows a relapsing-remitting course during
which patients experience various clinical symptoms, usually followed by periods of
remission. The neuropathogenesis of MS consists of two parallel destructive arms:
inflammatory demyelination and neurodegeneration. During the last two decades, we
have learned much about both aspects of the pathogenesis of MS. This expansion of
our knowledge had led to development of immunomodulatory agents for more effective
management of this previously untreatable disease.
Despite these enormous advances in our understanding of the pathogenesis of MS in
adult patients, much less is known about how MS affects the very young. Traditionally,
MS has been regarded as a “rare” disease of childhood. A review of MS literature,
however, demonstrates that at least 5 % of MS patients first manifest symptoms prior
to age 18 [[4], [5]]. Interestingly, more than 97 % of these patients initially experience a relapsing-remitting
disease [[6]]. Compared to adult patients, diagnosis of pediatric MS poses a challenge due to
a higher occurrence of other age-related white matter diseases in this age group.
In addition, children with MS develop disability at an earlier age than adults.
Currently, immunomodulating agents are recommended for management of adult patients
with MS. However, until recently, there has been no standard treatment for very early
onset of MS. Banwell et al. [[7]] retrospectively reviewed safety and tolerability of interferon-beta-1b in a cohort
of 43 children and adolescents. The group treated with IFN-beta-1b for a mean of 29.2
months tolerated treatment well. No safety issues were reported.
In this issue of Journal of Neuropediatrics, Pakdaman et al. [[8]] report the results of a prospective clinical trial utilizing a suboptimal dose
of IFN-beta-1a in children with early onset MS. The investigators randomized 16 consecutive
children with early onset relapsing-remitting MS to treatment with IFN-beta-1a 15
mcg IM once weekly or no treatment. Subjects were followed for four years and underwent
periodic neurological examination and assessment of safety measures. Study results
demonstrated that subjects who were randomized to treatment tolerated suboptimal doses
of IFN well with only mild side effects and no significant adverse events. At the
end of the trial, the treated subjects had less progression of disability compared
to the untreated subjects.
Both of these clinical trials utilizing beta-interferons in patients with early onset
MS provide strong evidence for the concept of early treatment approach in this patient
group, with the goal of slowing disease progression and delaying onset of disability.
The long-term effects of beta-interferons on children who are still maturing demand
further assessment, however.
